With more than three decades of experience as a healthcare and pharmaceutical executive, John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. During his six-year service as the CEO of Cambridge Therapeutics, John Klein developed knowledge of the Food and Drug Administration’s Code of Federal Regulations, as well as rules enacted by the State of New Jersey.

The New Jersey Department of Human Services (NJDHS) continues to make changes to state policy to ensure Medicaid patients have access to effective therapies for substance-abuse disorders. As of March 31, 2019, the state’s 1.7 million Medicaid enrollees are no longer required to gain approval from the managed-care plan that administers their insurance benefits before receiving medication-assisted treatment (MAT) for opiate addiction.

Viewed as the gold-standard for addressing opiate dependency, MAT involves prescribing patients opioid-replacement medications to minimize withdrawal symptoms and help calm addictive behaviors. In addition to assisting to eliminate insurance hurdles for state Medicaid enrollees, the NJDHS released new rules mandating all addiction-treatment facilities with such patients to offer MAT as a treatment option, effective July 1, 2019.